Collaboration Expanded to Accelerate Progress in MASH Diagnosis
Echosens and Boehringer Ingelheim have expanded their partnership to improve early detection, diagnosis, and care access for MASH.
Category: Unknown Origin & Other Cancer Types
Unknown Origin & Other Cancer Types
Latest
Unknown Origin & Other Cancer Types
Latest
New Biomarker Algorithm for Noninvasive Detection of Esophageal Cancer
A biomarker-based algorithm combined with a noninvasive test identifies those at risk for esophageal cancer or precancerous conditions.
Unknown Origin & Other Cancer Types
Latest
FDA Approves Thermo Fisher CDx for Glioma Treatment with VORANIGO
Thermo Fisher's CDx for identifying glioma patients eligible for treatment with Servier Pharmaceuticals' VORANIGO gets FDA approval.
Can a Mouthwash-Based Test Predict Head and Neck Cancer Recurrence?
Researchers are developing a mouthwash-based test to detect biomarkers that may help predict the recurrence of head and neck cancer.
Read More
FDA Approves Thermo Fisher’s HLA Sequencing System as CDx for Synovial Sarcoma T-Cell Receptor Therapy
Thermo Fisher’s SeCore CDx HLA A Sequencing System received FDA clearance as a CDx for TECELRA, a T-cell receptor therapy from Adaptimmune.
Read More
Blood Test May Guide Use of Multiple Myeloma Immunotherapy
A blood test measuring lymphocyte levels may predict the effectiveness of CAR-T immunotherapy in relapsed multiple myeloma patients.
Read More
Screening Tool Could up Hepatocellular Carcinoma Survival to 90%
A new machine-learning serum fusion-gene model shows promise in increasing hepatocellular carcinoma diagnostic accuracy and monitoring.
Read More
Researchers Identify Biomarker Linked to Renal Cancer Recurrence
Researcher identified a 15-gene signature biomarker that can stratify renal cancer patients into low or high risk of recurrence.
Read More
Rapid Cerebrospinal Fluid Test Decreases Time for Brain Tumors Diagnosis
A new genotyping test using cerebrospinal fluid can rapidly diagnose brain cancers, reducing the need for invasive biopsies.
Read More
New Biomarker Helps Detect Ovarian Cancer Years Before Conventional Diagnosis
Researchers discovered a novel immune-based biomarker that could pave the way for potential early detection of high-grade ovarian cancer.
Read More
Multi-Analyte Blood Test Outperforms Ultrasound in Early Liver Cancer Detection
A clinical trial shows that a Helio Genomics test outperforms ultrasound in detecting hepatocellular carcinoma in liver cirrhosis patients.
Read More
New Saliva-Based Test to Diagnose Oral Cavity CancerÂ
Salignostics has partnered with ARC Innovation at Sheba Medical Center to develop a saliva-based test for detecting oral cavity cancer.
Read More
Ovarian Cancer Detection Method Improvement Over CA125
Mercy BioAnalytics will present data showing that their Mercy Halo test significantly improves early detection of ovarian cancer.
Read More
New Biomarkers Identified for Improve Renal Cancer Diagnosis
Researchers discovered new biomarkers for renal cell carcinomas, enhancing the diagnosis of various subtypes.
Read More
Leptomeningeal Cancer Cell Diagnostic Assay Gets Clinical Trial Implementation
The tumor cell enumeration assay is a diagnostic test that is promising for establishing the diagnosis of leptomeningeal metastases.
Read More
Myriad Genetics Receives Patent for High-Definition MRD Assay
The U.S. Patent and Trademark Office issued a patent to Myriad Genetics aimed at strengthening its ability to deliver a MRD assay to market.Â
Read More
New Test Could Identify Aggressive Ovarian Cancers Early
A new algorithm may help identify high-risk precancerous lesions on the fallopian tubes thought to lead to a common form of ovarian cancer
Read More
Bladder Cancer LDT Receives Medicare Coverage
The Oncuria Bladder Cancer Tests, a DiaCarta validated lab developed test (LDT), received Medicare coverage effective Jan. 1, 2024.
Read More